Medtronic (MDT)
NYSE: MDT · Medical Devices · Galway,
Our rating: Neutral
Neutral reaffirmed at $94.17, moderate conviction, September 4, 2026.
Breaks if: The neutral call turns Positive if Medtronic reports net margin above 15% and sustains revenue growth above 7% for two consecutive quarterly filings. It turns Cautious if revenue growth falls below 5% year-over-year, or if net margin drops below 11%, in either of the next two quarterly reports.
Key figures
| Market value | $127.8B |
|---|---|
| Revenue, last 12 months | $37.5B |
| Net income, last 12 months | $5.2B |
| Free cash flow, last 12 months | $6.1B |
| Price to earnings | 24.4× |
| Free cash flow yield | 4.8% |
| Dividend yield | 2.9% |
| Operating margin | 18.1% |
| Return on equity | 10.7% |
| Beta to the S&P 500 | 0.31 |
| Volatility, annualized | 22.8% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| July 31, 2026 | $9.8B | 13.7% | $1.14 | $1.3B |
| April 24, 2026 | $9.8B | 9.9% | $0.97 | $2.1B |
| January 23, 2026 | $9.0B | 8.7% | $0.89 | $2.3B |
| October 24, 2025 | $9.0B | 6.6% | $1.07 | $457M |
| July 25, 2025 | $8.6B | 8.4% | $0.81 | $584M |
| April 25, 2025 | $8.9B | 3.9% | $0.82 | $2.1B |
| January 24, 2025 | $8.3B | 2.5% | $1.01 | $2.1B |
| October 25, 2024 | $8.4B | 5.2% | $0.99 | $554M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $9.83B: Claude 62%, Gemini 65%, Mistral 75%
- Diluted earnings per share are at least $1.07: Claude 55%, Gemini 75%, Mistral 68%
- Free cash flow for the quarter is at least $0.46B: Claude 72%, Gemini 90%, Mistral 62%
- Backlog at the end of the quarter is at least $0.40B: Claude 60%, Gemini 60%, Mistral 80%
9 ledger entries and 40 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.